AI assistant
Sending…
Tyra Biosciences, Inc. — Director's Dealing 2021
Sep 17, 2021
32575_dirs_2021-09-17_6c89ad0d-1690-4b42-93c9-9913a8881aa4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-17
Reporting Person: CHEN ISAN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-17 | Common Stock | C | 61444 | — | Acquired | 192783 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-17 | Series A Preferred Stock | $ | C | 16366 | Disposed | Common Stock (42509) | Direct | |
| 2021-09-17 | Series B Preferred Stock | $ | C | 7290 | Disposed | Common Stock (18935) | Direct |
Footnotes
F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: Includes 37,105 shares subject to repurchase by us, which are subject to vesting.
More from Tyra Biosciences, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 2
Interim / Quarterly Report
2026
May 13
Earnings Release
2026
May 13
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Board/Management Information
2026
Apr 17
Board/Management Information
2026
Apr 2
Regulatory Filings
2026
Mar 25
Director's Dealing
2026
Mar 17
Capital/Financing Update
2026
Mar 4